Filing Details

Accession Number:
0001209191-15-053888
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-06-16 17:11:54
Reporting Period:
2015-06-12
Filing Date:
2015-06-16
Accepted Time:
2015-06-16 17:11:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1373707 Tetraphase Pharmaceuticals Inc TTPH Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1572000 Charles David Lubner 480 Arsenal St. Suite 110
Watertown MA 02472
Svp And Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2015-06-12 10,000 $41.29 69,270 No 4 S Direct
Common Stock Acquisiton 2015-06-15 7,500 $2.03 76,770 No 4 M Direct
Common Stock Disposition 2015-06-15 7,500 $41.67 69,270 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2015-06-15 7,500 $0.00 7,500 $2.03
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
19,543 2022-06-05 No 4 M Direct
Footnotes
  1. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $41.28 to $41.41 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  2. The exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2015.
  3. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $40.63 to $42.73 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  4. This option vests as to 6.25% of the shares on September 6, 2012 and further vests as to 6.25% of the shares at the end of each of successive three-month period thereafter until June 6, 2016.